Phase 1a single ascending dose study of CNM-Au8 in healthy human volunteers

Trial Profile

Phase 1a single ascending dose study of CNM-Au8 in healthy human volunteers

Planning
Phase of Trial: Phase I

Latest Information Update: 10 May 2016

At a glance

  • Drugs CNM Au8 (Primary)
  • Indications Demyelinating disorders
  • Focus Adverse reactions
  • Most Recent Events

    • 10 May 2016 According to Clene Nanomedicine website, the US FDA has granted approval to proceed with this study.
    • 10 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top